Patients with gastrinomas that are also known to be part of neuroendocrine neoplasms must have to deal with two factors related to this tumor. First, controlling the high amounts by using medications that inhibit gastrin levels. The second part is stabilizing the tumor progression. Gastrinomas have a rate of 60–90% that will become malignant. Patients who do not seek medical treatment such anti-ulcer medication have high rate of recurrence and death secondary to ulcer disease. The prognosis of gastrinoma depends on the level of metastases of the tumor. If patients present with hepatic metastases they might have remaining life span of 1 year with a 5-year survival rate of 20–30%. In patients with localized tumor or localized lymph spread the survival rate of 5 years is 90%. Lastly, surgical resection of local tumor could lead to complete cure without recurrence in 20–25% of patients.
medical cause of Zollinger–Ellison syndrome
medical cause of Exocrine pancreatic insufficiency
medical cause of Gastritis
caption of Plummer–Vinson syndrome
symptom of Coeliac disease
complications of Crohn's disease
symptom of Autoimmune polyendocrine syndrome type 1
complications of Helicobacter pylori